Yangtze River Pharmaceutical Gp Nanjing Hailing Pharm Co. Ltd.

Primary objective: To study the pharmacokinetic behavior of the test formulation of brexpiprazole tablets (specification: 2 mg, Nanjing Hailing Pharmaceutical Co., Ltd., Yangtze River Pharmaceutical Group) and the reference formulation (REXULTI®, specification: 2 mg, Otsuka Pharmaceutical Co., Ltd.) in healthy subjects after a single oral administration under fasting and postprandial conditions, and to evaluate the bioequivalence of the two formulations. Secondary objective: To evaluate the safety of the test formulation and the reference formulation (trade name: REXULTI®) in healthy subjects.

Primary objective: To study the pharmacokinetic behavior of the test formulation (specification: 60 mg) and the reference formulation (Lixiana®, specification: 60 mg, Daiichi Sankyo Europe GmbH) of edoxaban tosylate tablets in healthy subjects after a single oral administration in the fasting or postprandial state, and to evaluate the bioequivalence of the two formulations. Secondary objective: To observe the safety of the test formulation and the reference formulation (trade name: Lixiana®) in healthy subjects.

Primary objective: In the fasting state, voriconazole dispersible tablets (specification: 200 mg,) produced by Nanjing Hailing Pharmaceutical Co., Ltd. of Yangtze River Pharmaceutical Group were used as the test preparation, and voriconazole tablets (Vifan®, specification: 200 mg,) produced by Pfizer Italia S.r.l. were used as the reference preparation to compare the pharmacokinetic characteristics of the two preparations in healthy subjects and evaluate the bioequivalence of the two preparations. Secondary objective: To observe the safety of the test preparation and the reference preparation (trade name: Vifan®) in healthy subjects.